New obesity drug GV101 shows promise in Mid-Stage trial
Disease control
Completed
This completed phase 2 trial tested different doses of the drug GV101 against a placebo for weight loss in 131 healthy adults with obesity. The main goal was to see how much weight participants lost after 16 weeks. Researchers compared the average weight change in each dose group…
Phase: PHASE2 • Sponsor: Graviton Bioscience Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC